Preclinical candidates and targets for tuberculosis therapy

Current Opinion in Investigational Drugs

Volumn 2, Issue 2, 2001, Pages 198-201

  Barry III, C E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Anaerobic; Bacillus; Cell wall; Genome; Microaerophilic; Mycobacterium; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTIINFECTIVE AGENT; CGI 17341; ETHAMBUTOL; ISOCITRATE LYASE; ISONIAZID; METRONIDAZOLE; NITRATE REDUCTASE; NITROFURAN DERIVATIVE; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; CLINICAL TRIAL; DRUG COST; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; GENE REPLICATION; GENE SEQUENCE; GENOME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; REVIEW; SHORT COURSE THERAPY; STRUCTURE ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS;

ANAEROBIOSIS; ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS;

EID: 0035116815     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Tuberculosis
2. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
3. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs
4. Antimyobacterial activities of novel levofloxacin analogues
5. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin
6. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex
7. Activity of quinolones against mycobacteria
8. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: Effects of a C-8 methoxyl group on survival in liquid media and in human macrophages
9. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis
10. Fluoroquinolones and tuberculosis
11. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis
12. N-[4-(1-1′-biphenyl)methyl]-4-(4-thiomorpholinylmethyl) benzenamines as non-oxazolidinone analogues of antimycobacterial U-100480
13. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
14. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity
15. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections
16. Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis
17. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention
18. Rifampicin in free combination with other antimicrobial drugs in non-Tb infections. Clinical data on 650 patients
19. Ecological antibiotic policy
20. Ecological consequences of broad spectrum versus narrow spectrum antibacterial therapy
21. Narrow versus broad-spectrum therapy
22. Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs
23. The impact of genomics on the search for novel tuberculosis drugs
24. Tuberculosis: Milking the genome for drug targets and vaccines. Novartis Foundation Symposium: Genetics and tuberculosis. Cape Town, South Africa, 18-20 November 1997
25. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization
26. Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid
27. Structure-activity studies leading to ethambutol, a new type of antituberculosis compound
28. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of non-replicating persistence
29. Dormancy of Mycobacterium tuberculosis and latency of disease
30. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions
31. Stationary phase-associated protein expression in Mycobacterium tuberculosis: Function of the mycobacterial α-crystallin homolog
32. The 16-kDa α-crystallin (Acr) protein of mycobacterium tuberculosis is required for growth in macrophages
33. Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice
34. Nitrate reduction as a marker for hypoxic shiftdown of Mycobacterium tuberculosis
35. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis
36. Potential radiosensitizing agents. Dinitroimidazoles
37. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
38. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase
39. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis